Extraintestinal manifestations of inflammatory bowel diseases

Journal of Clinical Gastroenterology

Volumn 40, Issue 6, 2006, Pages 467-475

  Kethu, Sripathi R ^a,b  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

Autoimmunity; Crohn disease; Extraintestinal manifestations; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ANTICOAGULANT AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLCHICINE; CORTICOSTEROID; CYANOCOBALAMIN; CYCLOSPORIN; CYCLOSPORIN A; DAPSONE; ETANERCEPT; IMMUNOMODULATING AGENT; INFLIXIMAB; IRON; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; POTASSIUM IODIDE; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ANTIBODY; URSODEOXYCHOLIC ACID; VITAMIN D;

ANEMIA; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTHROPATHY; AUTOIMMUNITY; CHOLELITHIASIS; CLINICAL FEATURE; ENTERITIS; EPISCLERITIS; ERYTHEMA NODOSUM; EXERCISE; FISTULA; FRACTURE; GENETICS; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HEREDITY; HUMAN; IMMUNITY; IMMUNOLOGY; IMMUNOMODULATION; KIDNEY DISEASE; MORBIDITY; MOUTH DISEASE; MUSCULOSKELETAL DISEASE; NEPHROLITHIASIS; NONHUMAN; OBSTRUCTIVE UROPATHY; OSTEOPOROSIS; PATHOGENESIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; REVIEW; SACROILIITIS; SKIN MANIFESTATION; THROMBOEMBOLISM; UVEITIS;

AUTOIMMUNITY; BILIARY TRACT DISEASES; EYE DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; JOINT DISEASES; SKIN DISEASES;

EID: 33748275080     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200607000-00003     Document Type: Review

References (92)

1. Greenstein AJ, Janowitz HD, Sachar DB. The extraintestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine. 1976;55:401-412.
2. Rankin GB, Watts HD, Melynk CS, et al. National Cooperative Crohn's Disease Study: Extraintestinal manifestations and perianal complications. Gastroenterology. 1979;77:914-920.
3. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23:29-34.
4. Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol. 2003;9:2300-2307.
5. Ricart E, Panaccione R, Loftus EV Jr, et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2004;10:207-214.
6. Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease. New insights into autoimmune pathogenesis. Dig Dis Sci. 1999;44:1-13.
7. Salvarani C, Vlachonikolis IG, van der Heijde DM, et al. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol. 2001;36:1307-1313.
8. Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116-1122.
9. Yap LM, Ahmad T, Jewell DP. The contribution of HLA genes to IBD susceptibility and phenotype. Best Pract Res Clin Gastroenterol. 2004;18:577-596.
10. Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002;70:845-857.
11. Peeters H, Vander Cruyssen B, Laukens D, et al. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. Ann Rheum Dis. 2004;63:1131-1134.
12. Orchard TR, Thiyagaraja S, Welsh KI, et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology. 2000;118:274-278.
13. Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180:2359-2364.
14. Grant AJ, Lalor PF, Salmi M, et al. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet. 200212;359:150-157.
15. Salmi M, Jalkanen S. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. J Immunol. 2001;166:4650-4657.
16. Salmi M, Jalkanen S. Endothelial ligands and homing of mucosal leukocytes in extraintestinal manifestations of IBD. Inflamm Bowel Dis. 1998;4:149-156.
17. Orchard TR, Wordsworth BP, Jewel DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998;42:387-391.
18. Orchard TR. Arthritis associated with inflammatory bowel disease. In: Bayless TM, Hanauer SB, eds. Advanced Therapy of Inflammatory Bowel Disease. 1st ed. Hamilton, Ontario: BC Decker Inc., 2001:279-282.
19. Farmer RG, Hawk WA, Turnbull RB Jr Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology. 1975;68:627-635.
20. Palm O, Moum B, Ongre A, et al. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol. 2002;29:511-515.
21. de Vlam K, Mielants H, Cuvelier C, et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol. 2000;27:2860-2865.
22. Steer S, Jones H, Hibbert J, et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. J Rheumatol. 2003;30:518-522.
23. Scott WW Jr, Fishman EK, Kuhlman JE, et al. Computed tomography evaluation of the sacroiliac joints in Crohn disease. Radiologic/clinical correlation. Skeletal Radiol. 1990;19:207-210.
24. Helliwell PS, Hickling P, Wright V. Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease,psoriasis, and reactive arthritis? Ann Rheum Dis. 1998;57:135-140.
25. McEwen C, DiTata D, Lingg C, et al. Ankylosing spondylitis and spondylitis accompanying ulcerative colitis, regional enteritis, psoriasis and Reiter's disease. A comparative study. Arthritis Rheum. 1971;14:291-318.
26. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet. 2002;359:1187-1193.
27. Nikas SN, Alamanos Y, Voulgari PV, et al. Infliximab therapy in ankylosing spondylitis: an observational study. Ann Rheum Dis. 2005;64:940-942.
28. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346:1349-1356.
29. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48:1667-1675.
30. Maksymowych WP, Inman RD, Gladman D, et al. Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. J Rheumatol. 2003;30:1356-1363.
31. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795-841.
32. Card T, West J, Hubbard R, et al. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut. 2004;53:251-255.
33. Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med. 200021;133:795-799.
34. Vanstaa TP, Cooper C, Brusse LS, et al. Inflammatory bowel disease and the risk of fracture. Gastroenterology. 2003;125:1591-1597.
35. Loftus EV Jr, Achenbach SJ, Sandborn WJ, et al. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2003;1:465-473.
36. Loftus EV Jr, Crowson CS, Sandborn WJ, et al. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology. 2002;123:468-475.
37. Bernstein CN. Another look at fracture risk in IBD. Inflamm Bowel Dis. 2004;10:886-887.
38. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292:490-495.
39. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402:304-309.
40. Franchimont N, Reenaers C, Lambert C, et al. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clin Exp Immunol. 2004;138:491-498.
41. Gregory B, Ho VC. Cutaneous manifestations of gastrointestinal disorders. Part II. J Am Acad Dermatol. 1992;26:371-383.
42. Krull EA. Erythema nodosum: a review. Cutis 1987;21:806-810.
43. Requena L, Requena C. Erythema nodosum. Dermatol Online J. 2002;8:4.
44. Fleisher M, Rubin S, Levine A, et al. Infliximab in the treatment of steroid refractory erythema nodosum of IBD. Gastroenterology. 2002;122:A618.
45. Callen JP. Pyoderma gangrenosum. Lancet. 1998;351:581-585.
46. Kaufman I, Caspi D, Yeshurun D, et al. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int. 2005;25:406-410.
47. Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98:1821-1826.
48. Friedman S, Marion JF, Scherl E, et al. Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis. 2001;7:1-7.
49. Reichrath J, Bens G, Bonowitz A, et al. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53:273-283.
50. D'Inca R, Fagiuoli S, Sturniolo GC. Tacrolimus to treat pyoderma gangrenosum resistant to cyclosporine. Ann Intern Med. 1998;128:783-784.
51. Monsen U, Sorstad J, Hellers G, et al. Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol. 1990;85:711.
52. Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111:352-356.
53. Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125:1364-1369.
54. Schrumpf E, Fausa O, Elgjo K, et al. Hepatobiliary complications of inflammatory bowel disease. Semin Liver Dis. 1988; 8:201-209.
55. Olsson R, Danielsson A, Jarnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology. 1991; 100:1319-1323.
56. Portincasa P, Vacca M, Moschetta A, et al. Primary sclerosing cholangitis: updates in diagnosis and therapy. World J Gastroenterol. 2005;11:7-16.
57. Roozendaal C, de Jong MA, van den Berg AP, et al. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J Hepatol. 2000;32:734-741.
58. Seibold F, Weber P, Schoning A, et al. Neutrophil antibodies (pANCA) in chronic liver disease and inflammatory bowel disease: do they react with different antigens? Eur J Gastroenterol Hepatol. 1996;8:1095-1100.
59. Broome U, Olsson R, Loof L, et al. Natural history and prognostic in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38:610-615.
60. Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology. 1989;10:430-436.
61. Baluyut AR, Sherman S, Lehman GA, et al. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc. 2001;53:308-312.
62. Fraquelli M, Losco A, Visentin S, et al. Gallstone disease and related risk factors in patients with Crohn disease:analysis of 330 consecutive cases. Arch Intern Med. 2001;161:2201-2204.
63. Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol. 2003;36:417-420.
64. Pereira SP, Bain IM, Kumar D, et al. Bile composition in inflammatory bowel disease: ileal disease and colectomy,but not colitis, induce lithogenic bile. Aliment Pharmacol Ther. 2003;17: 923-933.
65. Kethu SR, Feller ER. Gallstones and cholecystitis. In: Leppert PC, Peipert JF, eds. Primary Care for Women. 2nd ed. Phildelphia, PA: Lippincott, Williams & Wilkins; 2004.
66. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med. 2004;116:44S-49S.
67. Gasche C. Anemia in IBD: the overlooked villain. Inflamm Bowel Dis. 2000;6:142-150.
68. Cronin CC, Shanahan F. Anemia in patients with chronic inflammatory bowel disease. Am J Gastroenterol. 2001;96:2296-2298.
69. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut. 2004;53:1190-1197.
70. Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med. 1996;334:619-623.
71. Quera R, Shanahan F. Thromboembolism-an important manifestation of inflammatory bowel disease. Am J Gastroenterol. 2004;99:1971-1973.
72. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004;99:97-101.
73. Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001;85:430-434.
74. Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut. 2004;53:542-548.
75. Kader HA, Berman WF, Al-Seraihy AS, et al. Prevalence of factor V G1691A (Leiden), prothrombin G20210A, and methylene tetrahydrofolate reductase C677T thrombophilic mutations in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2002;35:629-635.
76. Vecchi M, Sacchi E, Saibeni S, et al. Inflammatory bowel diseases are not associated with major hereditary conditions predisposing to thrombosis. Dig Dis Sci. 2000;45:1465-1469.
77. Saibeni S, Bottasso B, Spina L, et al. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol. 2004;99:1966-1970.
78. Bjerregaard LT, Nederby NJ, Fredholm L, et al. Hyperhomocysteinaemia, coagulation pathway activation and thrombophilia in patients with inflammatory bowel disease. Scand J Gastroenterol. 2002;37:62-67.
79. Shield DE, Lytton B, Weiss RM, et al. Urologic complications of inflammatory bowel disease. J Urol. 1976;115:701-706.
80. Ben-Ami H, Ginesin Y, Behar DM, et al. Diagnosis and treatment of urinary tract complications in Crohn's disease: an experience over 15 years. Can J Gastroenterol. 2002;16:225-229.
81. Knudsen L, Marcussen H, Fleckenstein P, et al. Urolithiasis in chronic inflammatory bowel disease. Scand J Gastroenterol. 1978;13:433-436.
82. Pardi DS, Tremaine WJ, Sandborn WJ, McCarthy JT. Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol. 1998;93:504-514.
83. McConnell N, Campbell S, Gillanders I, et al. Risk factors for developing renal stones in inflammatory bowel disease. BJU Int. 2002;89:835-841.
84. Trinchieri A, Lizzano R, Castelnuovo C, et al. Urinary patterns of patients with renal stones associated with chronic inflammatory bowel disease. Arch Ital Urol Androl. 2002;74:61-64.
85. Siminovitch JM, Fazio VW. Ureteral obstruction secondary to Crohn's disease: a need for ureterolysis? Am J Surg. 1980;139:95-98.
86. Sato S, Sasaki I, Naito H, et al. Management of urinary complications in Crohn's disease. Surg Today. 1999;29:713-717.
87. Kyle J. Urinary complications of Crohn's disease. World J Surg. 1980;4:153-160.
88. Ochsenkuhn T, Goke B, Sackmann M. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease. Am J Gastroenterol. 2002;97:2022-2025.
89. SongurNecla MD, Songur Yldran MD, et al. Pulmonary function tests and high-resolution CT in the detection of pulmonary involvement in inflammatory bowel disease. J Clin Gastroenterol. 2003;37:292-298.
90. Storch I, Sachar D, Katz S. Pulmonary manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2003;9:104-115.
91. Lossos A, River Y, Eliakim A, Steiner I. Neurologic aspects of inflammatory bowel disease. Neurology. 1995;45:416-421.
92. Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis. 2001;7:295-300.